Masemann, Dörthe Meissner, Ramona Schied, Tanja Lichty, Brian D Rapp, Ulf R Wixler, Viktor Ludwig, Stephan
Published in
Oncoimmunology
Non-small cell lung cancers (NSCLCs) establish a highly immunosuppressive tumor microenvironment supporting cancer growth. To interfere with cancer-mediated immunosuppression, selective immune-checkpoint inhibitors (ICIs) have been approved as a standard-of-care treatment for NSCLCs. However, the majority of patients poorly respond to ICI-based imm...
Phanthunane, C. Wijers, R. de Herdt, M. Langeveld, T.P.M. Koljenovic, S. Dasgupta, S. Sleijfer, S. Baatenburg de Jong, R. J. Hardillo, J. Balcioglu, H. E.
...
Published in
Oncoimmunology
In oral-cancer, the number of tumor-infiltrating lymphocytes (TILs) associates with improved survival, yet the prognostic value of the cellular composition and localization of TILs is not defined. We quantified densities, localizations, and cellular networks of lymphocyte populations in 138 patients with T1-T2 primary oral-tongue squamous cell carc...
Valachis, Antonios Rosén, Camilla Koliadi, Anthoula Digkas, Evangelos Gustavsson, Alice Nearchou, Andreas Ullenhag, Gustav J
Published in
Oncoimmunology
In international guidelines, influenza vaccination is recommended to cancer patients receiving antitumor treatment. Whether this recommendation should include patients treated with the recently introduced and now widely used checkpoint inhibitors (CPIs) is unclear. The immune hyperactivation after vaccination in a patient on CPI treatment may stren...
Bindea, Gabriela Mlecnik, Bernhard Galon, Jérôme
Published in
Oncoimmunology
The tumor microenvironment includes a complex network of cytokines and chemokines that contribute to shaping the intratumoral immune reaction. Understanding the mechanisms leading to immune-hot (Immunoscore-high) altered (excluded and immunosuppressed) and cold tumors are of critical importance for successful anti-cancer therapies. Two essential me...
De Martino, Mara Daviaud, Camille Vanpouille-Box, Claire
Published in
Oncoimmunology
The mechanisms accountable for the infiltration of regulatory T cells into an irradiated tumor remain elusive. In our recent study, we demonstrate that activin A promotes regulatory T cells in tumors, and impairs anti-tumor immune responses induced by radiotherapy and TGF-β blockade. Dual blockade of activin A and TGF-β may be necessary to reduce r...
Pan, Chuqing Wang, Yu Liu, Qianwen Hu, Yihuai Fu, Jianhua Xie, Xiuying Zhang, Shuishen Xi, Mian Wen, Jing
Published in
Oncoimmunology
The tumor microenvironment (TME) of esophageal squamous cell carcinoma (ESCC) impacts tumor progression but is poorly understood. We obtained tumor tissues from 279 patients after esophagectomy and characterized the TME in intraepithelial and stromal regions using multiplex fluorescent immunohistochemistry (mfIHC). A heterogeneous immune population...
Patrinely, J. Randall Jr. McGuigan, Ben Chandra, Sunandana Fenton, Sarah E. Chowdhary, Akansha Kennedy, Lucy B. Mooradian, Meghan J. Palmeri, Marisa Portal, Daniella Horst, Sara N.
...
Published in
Oncoimmunology
Immune checkpoint inhibitors (ICI) predispose patients to immune-related adverse events (irAEs). Although hepatitis is a potentially lethal toxicity, the timing and outcomes have not been well described. In this retrospective study, patients from six international institutions were included if they were treated with ICIs and developed immune-relate...
Boivin, Gaël Ancey, Pierre-Benoit Vuillefroy de Silly, Romain Kalambaden, Pradeep Contat, Caroline Petit, Benoit Ollivier, Jonathan Bourhis, Jean Meylan, Etienne Vozenin, Marie-Catherine
...
Published in
Oncoimmunology
The anti-Ly6G antibody is used to deplete Ly6Gpos neutrophils and study their role in diverse pathologies. However, depletion is never absolute, as Ly6Glow neutrophils resistant to depletion rapidly emerge. Studying the functionality of these residual neutrophils is necessary to interpret anti-Ly6G-based experimental designs. In vitro , we found an...
Jordakieva, Galateja Bianchini, Rodolfo Reichhold, Daniel Piehslinger, Jakob Groschopf, Alina Jensen, Sebastian A. Mearini, Ettore Nocentini, Giuseppe Crevenna, Richard Zlabinger, Gerhard J.
...
Published in
Oncoimmunology
IgG4 subclass antibodies are expressed in alternative Th2 environments featuring high IL-10 expression, including several solid tumors such as melanoma. To induce tolerance, allergen immunotherapy mediates antibody class switching from pro-inflammatory IgE to anti-inflammatory IgG4. We previously reported that IgG4 drives allergic M2 macrophages to...
Petriv, Nataliia Neubert, Lavinia Vatashchuk, Myroslava Timrott, Kai Suo, Huizhen Hochnadel, Inga Huber, René Petzold, Christina Hrushchenko, Anastasiia Yatsenko, Andriy S.
...
Published in
Oncoimmunology
